Enrollment and Eligibility
Age: 18 years or older
Disease: Pathologically proven diagnosis of prostate adenocarcinoma within 180 days of registration at moderate to high-risk for recurrence as determined by Gleason score, PSA, palpation and biopsies.
Study Phase: Phase III
Purpose: This randomized Phase III trial studies androgen-deprivation therapy and radiation therapy in treating patients with prostate cancer.